Antimicrobial Peptides (AMPs)
Leech-derived defense molecules with translational potential against drug-resistant pathogens
Last updated: March 14, 2026
Medicinal leeches produce a diverse arsenal of antimicrobial peptides (AMPs) as part of their innate immune defense. These molecules protect the leech gut environment during months-long blood digestion and represent a largely untapped source of novel antimicrobial candidates at a time when antibiotic resistance is a critical global health threat.
Preclinical Research
Key AMP Families
Hirunipins
Recently characterized cysteine-rich peptides from Hirudo medicinalis salivary glands. Active against both Gram-positive and Gram-negative bacteria, including multidrug-resistant strains. Mechanism involves membrane disruption via a three-step oligomerization-dependent translocation (ODT) model.
Theromacin & Theromyzin
AMPs identified in Theromyzon tessulatum (a related leech species). Theromacin is an 8.2 kDa cysteine-stabilized peptide with broad-spectrum activity. Both contribute to understanding the leech AMP repertoire across species.
Destabilase-Lysozyme
A dual-function enzyme with both isopeptidase (fibrinolytic) and muramidase (antimicrobial) activities. Cleaves peptidoglycan in bacterial cell walls while simultaneously acting as a thrombolytic agent. See
Peptide B
A chloride channel-inhibiting peptide with secondary antimicrobial properties. Part of the broader salivary defense system that maintains sterility during blood storage in the crop.
Mechanisms of Action
Leech AMPs employ multiple mechanisms to kill or inhibit bacteria:
- Membrane disruption: Cationic AMPs interact with negatively charged bacterial membranes, forming pores or causing lysis. Hirunipins use a three-step process: surface binding, oligomerization, and translocation.
- Biofilm disruption: Certain leech AMPs penetrate and disrupt bacterial biofilms, which are a major barrier to conventional antibiotic efficacy in chronic infections.
- Synergy with antibiotics: Preclinical data shows fractional inhibitory concentration index (FICI) values indicating synergistic or additive effects when leech AMPs are combined with conventional antibiotics.
- Anti-inflammatory modulation: Some leech AMPs reduce pro-inflammatory cytokine release (TNF-alpha, IL-6, IL-1beta), potentially addressing the dual challenge of infection and inflammation.
Translational Relevance
With the WHO identifying antimicrobial resistance as a top-10 global health threat and the clinical antibiotic pipeline stagnating, leech-derived AMPs represent a promising bioprospecting resource. Key advantages include novel mechanisms of action that differ from conventional antibiotics, broad-spectrum activity against drug-resistant strains, and potential for combination therapy. Research is at the preclinical stage.
For a detailed analysis of the latest research, including the 2025 hirunipins study, see our Research: Novel Leech Antimicrobial Peptides article.
Research Stage
Related Resources
Salivary Gland Complex
434+ proteins across anticoagulant, anti-inflammatory, and antimicrobial functional groups.
Learn more →
Destabilase
Dual-function enzyme — fibrinolytic AND antimicrobial activities.
Learn more →
Drug Development
From leech compounds to FDA-approved drugs and the research pipeline.
Learn more →